Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

January 11, 2021

In our exclusive interview, Dr. Powles and Dr. Rini provide insight into an analysis of the phase 3 IMvigor010 study and its implications for circulating tumor DNA as a biomarker in urothelial cancer and beyond.

December 02, 2020

Jordan D. Berlin, MD, discusses the unmet needs in pancreatic cancer treatment and ongoing research efforts with nanoliposomal irinotecan.

November 25, 2020

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

November 23, 2020

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

November 19, 2020

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

November 16, 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

November 05, 2020

Douglas B. Johnson, MD, MSCI, discusses his research examining the impact of body composition on outcomes from anti–PD-1 with or without anti–CTLA-4 therapies in melanoma and other biomarkers under exploration.

October 29, 2020

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

October 07, 2020

In recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.

September 29, 2020

Vanderbilt-Ingram Cancer Center received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute and places it once again in a top group of NCI Comprehensive Cancer Centers.

September 24, 2020

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

September 15, 2020

Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.

August 28, 2020

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

August 20, 2020

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

August 18, 2020

Jordan D. Berlin, MD, discusses the importance of more data and more effective treatment regimens in metastatic pancreatic cancer, despite the number of treatment options currently available.

May 15, 2020

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

May 14, 2020

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

May 08, 2020

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

April 28, 2020

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.

April 23, 2020

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.